Targeting BCL-2 regulated apoptosis in cancer

Campbell, K. J. and Tait, S. W.J. (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8(5), 180002. (doi:10.1098/rsob.180002) (PMID:29769323) (PMCID:PMC5990650)

Campbell, K. J. and Tait, S. W.J. (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8(5), 180002. (doi:10.1098/rsob.180002) (PMID:29769323) (PMCID:PMC5990650)

[img]
Preview
Text
163056.pdf - Published Version
Available under License Creative Commons Attribution.

855kB

Abstract

The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we discuss the BCL-2 family, their deregulation in cancer and recent pharmaceutical developments to target specific members of this family as cancer therapy.

Item Type:Articles
Additional Information:Research in our laboratory is supported by Cancer Research UK, Breast Cancer Now and Tenovus Scotland.
Keywords:BAX/BAK, BCL-2 family, apoptosis.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Campbell, Dr Kirsteen and Tait, Professor Stephen
Authors: Campbell, K. J., and Tait, S. W.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Open Biology
Publisher:The Royal Society Publishing
ISSN:2046-2441
ISSN (Online):2046-2441
Published Online:16 May 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Open Biology 8(5): 180002
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record